Defilade Capital Management, L.P. 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
Defilade Capital Management, L.P. disclosed 31 US equity positions worth $712.2m in its Q1 2026 13F filing. The largest position was ZBH at 7.4% of the reported book, followed by HSIC and BDX.
What did Defilade Capital Management, L.P. own in Q1 2026? Top 31 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | ZBH ZIMMER BIOMET HOLDINGS INC | Healthcare | 7.4% | $52.4m | 579,161 | – | |
| 2 | HSIC SCHEIN HENRY INC | Healthcare | 6.5% | $46.0m | 624,037 | – | |
| 3 | BDX BECTON DICKINSON & CO | Healthcare | 6.2% | $43.9m | 279,210 | – | |
| 4 | PFE PFIZER INC | Healthcare | 5.8% | $41.1m | 1,464,129 | – | |
| 5 | DXCM DEXCOM INC | Healthcare | 4.8% | $33.8m | 538,762 | – | |
| 6 | ICUI ICU MED INC | Healthcare | 4.6% | $32.8m | 254,291 | – | |
| 7 | INSM INSMED INC | Healthcare | 4.5% | $31.9m | 194,909 | – | |
| 8 | ISRG INTUITIVE SURGICAL INC | Healthcare | 4.4% | $31.2m | 67,681 | – | |
| 9 | RVMD REVOLUTION MEDICINES INC | Healthcare | 4.3% | $30.7m | 315,972 | – | |
| 10 | GMED GLOBUS MED INC | Healthcare | 4.3% | $30.5m | 354,350 | – | |
| 11 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 3.9% | $27.7m | 209,932 | – | |
| 12 | DNLI DENALI THERAPEUTICS INC | Healthcare | 3.7% | $26.1m | 1,359,969 | – | |
| 13 | PTCT PTC THERAPEUTICS INC | Healthcare | 3.6% | $25.6m | 376,165 | – | |
| 14 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 3.1% | $22.4m | 1,504,536 | – | |
| 15 | ELAN ELANCO ANIMAL HEALTH INC | Healthcare | 3.1% | $22.3m | 931,121 | – | |
| 16 | PACS PACS GROUP INC | Healthcare | 2.7% | $19.4m | 604,180 | – | |
| 17 | LLY ELI LILLY & CO | Healthcare | 2.7% | $19.0m | 20,696 | – | |
| 18 | LNTH LANTHEUS HLDGS INC | Healthcare | 2.7% | $18.9m | 249,401 | – | |
| 19 | ITGR INTEGER HLDGS CORP | Healthcare | 2.6% | $18.7m | 213,027 | – | |
| 20 | BIIB BIOGEN INC | Healthcare | 2.5% | $17.7m | 96,289 | – | |
| 21 | EVMN EVOMMUNE INC | 2.2% | $15.6m | 678,589 | – | ||
| 22 | TNDM TANDEM DIABETES CARE INC | Healthcare | 2.1% | $14.6m | 761,905 | – | |
| 23 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.9% | $13.6m | 352,590 | – | |
| 24 | NUVALENT INC | 1.9% | $13.3m | 129,950 | – | ||
| 25 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 1.8% | $12.6m | 1,487,645 | – | |
| 26 | ASND ASCENDIS PHARMA A/S | Healthcare | 1.7% | $11.9m | 51,895 | – | |
| 27 | ALGN ALIGN TECHNOLOGY INC | Healthcare | 1.6% | $11.5m | 67,332 | – | |
| 28 | ELDN ELEDON PHARMACEUTICALS INC | 1.5% | $11.0m | 3,564,127 | – | ||
| 29 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.5% | $10.7m | 842,928 | – | |
| 30 | BHVN BIOHAVEN LTD | Healthcare | 0.4% | $2.7m | 315,944 | – | |
| 31 | MREO MEREO BIOPHARMA GROUP PLC | Healthcare | 0.4% | $2.5m | 7,558,756 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.